DURECT Corporation Appoints Dr. Terrence F. Blaschke to Its Board of Directors

Download PDF:

CUPERTINO, Calif., Dec. 18 /PRNewswire-FirstCall/ — DURECT Corporation
(Nasdaq: DRRX) today announced that Terrence F. Blaschke, M.D. has joined its
Board of Directors. Dr. Blaschke has served on the faculty of Stanford
University for over 30 years and is Professor of Medicine and Molecular
Pharmacology (Active Emeritus) at the Stanford University School of Medicine.
During the course of his career, Dr. Blaschke has served as an independent
consultant working with a number of leading pharmaceutical and biotechnology
companies. Dr. Blaschke was formerly a Board member of Therapeutic Discovery
Corporation and Crescendo Pharmaceuticals, two publicly-traded companies that
successfully developed products (including CONCERTA(R), DITROPAN XL(R) and
Viadur(R)) that played a substantial role in ALZA’s maturation into a
specialty pharmaceutical company prior to its acquisition by Johnson &
Johnson. He has also worked as a special government employee for the U.S. Food
and Drug Administration (“FDA”) and has served as the chairman of the FDA’s
Generic Drugs Advisory Committee.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO )

“Dr. Blaschke is a physician with extensive experience in pharmacology as
it impacts on product performance and drug development, garnered both within
Stanford and through his advisory work with a number of leading pharmaceutical
companies and the FDA,” said Dr. Felix Theeuwes, DURECT’s Chairman and Chief
Scientific Officer. “We look forward to the additional perspective he will
bring to our Board of Directors as we continually assess how to prioritize our
drug development opportunities and as we embark on our goal to transform into
a specialty pharmaceutical company.”

“DURECT’s five drug delivery technologies have wide potential
applicability to a very large number of drug development situations and I look
forward to assisting management and the Board of Directors in determining from
a science and business perspective how these opportunities should be
prioritized and exploited,” said Dr. Blaschke.

About DURECT Corporation

DURECT Corporation is an emerging specialty pharmaceutical company focused
on the development of pharmaceutical systems based on its proprietary drug
delivery platform technologies focused on treating chronic and episodic
diseases and conditions. The Company currently has a number of late-stage
pharmaceutical products in development initially focused on significant unmet
medical needs in pain management, with a number of research programs underway
in a variety of other therapeutic areas. For more information, please visit
http://www.www.durect.com .

DURECT Forward-Looking Statement

The statements in this press release regarding DURECT’s potential product
development opportunities and goal to transform into a specialty
pharmaceutical company are forward-looking statements involving risks and
uncertainties that can cause actual results to differ materially from those in
such forward-looking statements. Potential risks and uncertainties include,
but are not limited to, DURECT’s ability to develop, manufacture, obtain
regulatory approval for and commercialize its product candidates, manage its
growth and expenses, manage relationships with third parties, finance its
activities and operations, as well as marketplace acceptance of its product
candidates. Further information regarding these and other risks is included in
DURECT’s Form 10-Q dated November 3, 2006 under the heading “Risk Factors.”

CONTACT: Schond L. Greenway, Vice President, Investor Relations and
Strategic Planning of DURECT Corporation, +1-408-777-1417; or Jeremiah Hall,
Senior Vice President of Feinstein Kean Healthcare, +1-415-677-2700,
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
Web site: http://www.www.durect.com

Scroll to Top